We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
- Authors
Neurohr, Claus; Hoffmann, Anna L.; Huppmann, Patrick; Herrera, Vivian A.; Ihle, Franziska; Leuschner, Stefan; von Wulffen, Werner; Meis, Tobias; Baezner, Carlos; Leuchte, Hanno; Baumgartner, Rainer; Zimmermann, Gregor; Behr, Juergen
- Abstract
<bold>Background: </bold>Lymphangioleiomyomatosis (LAM) is a rare lung disease characterised by progressive airflow obstruction. No effective medical treatment is available but therapy with sirolimus has shown some promise. The aim of this observational study was to evaluate sirolimus in progressive LAM.<bold>Methods: </bold>Sirolimus (trough level 5 - 10 ng/ml) was administered to ten female patients (42.4 ± 11.9 years) with documented progression. Serial pulmonary function tests and six-minute-walk-distance (6-MWD) assessments were performed.<bold>Results: </bold>The mean loss of FEV1 was -2.30 ± 0.52 ml/day before therapy and a significant mean gain of FEV1 of 1.19 ± 0.26 ml/day was detected during treatment (p = 0.001). Mean FEV1 and FVC at baseline were 1.12 ± 0.15 l (36.1 ± 4.5%pred.) and 2.47 ± 0.25 l (69.2 ± 6.5%pred.), respectively. At three and six months during follow-up a significant increase of FEV1 and FVC was demonstrated (3 months ΔFEV1: 220 ± 82 ml, p = 0.024; 6 months ΔFEV1: 345 ± 58 ml, p = 0.001); (3 months ΔFVC: 360 ± 141 ml, p = 0.031; 6 months ΔFVC: 488 ± 138 ml, p = 0.006). Sirolimus was discontinued in 3 patients because of serious recurrent lower respiratory tract infection or sirolimus-induced pneumonitis. No deaths and no pneumothoraces occurred during therapy.<bold>Conclusions: </bold>Our data suggest that sirolimus might be considered as a therapeutic option in rapidly declining LAM patients. However, sirolimus administration may be associated with severe respiratory adverse events requiring treatment cessation in some patients. Moreover, discontinuation of sirolimus is mandatory prior to lung transplantation.
- Subjects
GERMANY; RAPAMYCIN; LYMPHANGIOMYOMATOSIS; PULMONARY function tests; RESPIRATORY infections; PNEUMOTHORAX; DRUG side effects; THERAPEUTICS; DISEASE progression; EXERCISE tests; PNEUMONIA; LUNGS; TIME; CONVALESCENCE; LUNG tumors; RESPIRATORY measurements; LYMPHATIC tumors; TREATMENT effectiveness; FORCED expiratory volume; RESPIRATION
- Publication
Respiratory Research, 2011, Vol 12, Issue 5, p1
- ISSN
1465-9921
- Publication type
journal article
- DOI
10.1186/1465-9921-12-66